EPISODE · Nov 1, 2024 · 12 MIN
Highlights from AAO 2024
from Meeting Mic · host Healio
In this episode of Meeting Mic, we bring you pearls and perspectives from the American Academy of Ophthalmology 2024 Meeting with a focus on AMD and retina. David A. Eichenbaum, MD, discusses results from a phase 1 trial investigating axitinib for the treatment of neovascular age-related macular degeneration. :28 Douglas Love discusses the company's phase 3 program in geographic atrophy. 2:37 Pravin U. Dugel, MD, discusses the next steps for the phase 3 SOL-1 and SOL-R studies. 3:54 Jeremiah Brown, MS, MD, presents results from the phase 4 Elevatum trial investigating faricimab for diabetic macular edema. 5:17 Read the full coverage here: https://www.healio.com/news/ophthalmology/20241024/video-axitinib-shows-clinically-meaningful-treatment-burden-reduction-in-wet-amd https://www.healio.com/news/ophthalmology/20241023/video-phase-3-geographic-atrophy-program-focuses-on-visual-acuity https://www.healio.com/news/ophthalmology/20241021/video-ocular-therapeutix-shares-update-on-phase-3-axpaxli-studies https://www.healio.com/news/ophthalmology/20241018/video-faricimab-shows-amazing-outcomes-in-underrepresented-patients-with-dme Teleretinal screening for diabetic retinopathy beneficial Source: Weng CY. The use of teleretinal screening for diabetic retinopathy. Presented at: American Academy of Ophthalmology meeting; Oct. 18-21, 2024; Chicago. Oral treatment aims to reduce GA progression by slowing vitamin A dimerization Source: Melamud A. Gildeuretinol in geographic atrophy: Results from SAGA, a 2-year, randomized, double-masked, placebo-controlled Study. Presented at: American Academy of Ophthalmology meeting; Oct. 18-21, 2024; Chicago. Fas inhibitor shows benefit in some cases of macula-off rhegmatogenous retinal detachment Source: Borkar DS. Fas inhibition with intravitreal ONL1204 for the treatment of macula-off rhegmatogenous retinal detachment: Results from a phase 2 study. Presented at: American Academy of Ophthalmology meeting; Oct. 18-21, 2024; Chicago. Disclosures: Brown reports being an investigator and speaker for Genentech and a researcher for EyeBio, Regeneron and Regenxbio. Dugel reports being executive chairman, president and CEO of Ocular Therapeutix. Eichenbaum reports being a consultant and investigator for Ocular Therapeutix. Love reports being president and CEO of Annexon Biosciences.
NOW PLAYING
Highlights from AAO 2024
No transcript for this episode yet
Similar Episodes
Feb 26, 2026 ·51m
Feb 25, 2026 ·3m
Feb 25, 2026 ·5m
Feb 25, 2026 ·27m
Feb 25, 2026 ·37m
Feb 25, 2026 ·109m